Mei Elsayed
Heidelberg University · 8 works · 307 citations · h-index 4
Top works
- EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non‐small cell lung cancer
- Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma
- Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
- Therapeutic Sequencing in ALK+ NSCLC
- Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases
- EML4-ALK fusion variant V3 confers early treatment failure with first and second generation ALK TKI
- TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC
- TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma